- Lead asset= LYPDISO (MAT9001) is a prescription-only omega-3 free fatty acid similar to AMRN’s Vascepa which was FDA approved last year to decrease the risk of heart disease
- MTNB leverages its proprietary LIPID NANO-CRYSTAL (LNC) platform to deliver a broad range of potent medicines. Watch this video to see how the tech works
- Additional assets = MAT2501, and MAT2203 which are orally-administered LNC formulations of antibiotic and antifungal medications, respectively
You must log in to post a comment.